Henry Schein authorizes repurchase of $200M shares of common stock

Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of health care products and services to office-based practitioners, today announced that its Board of Directors has authorized the repurchase of up to $200 million of shares of the Company's common stock.  This program is in addition to the $100 million repurchase program announced in November 2010, which has been fully executed.  

The Company currently has approximately 91 million shares outstanding, and this new authorization represents approximately 3.5 percent of shares outstanding at the current stock price. Purchases may be made from time to time in the open market, or through negotiated transactions.

"During the first six months of the current fiscal year Henry Schein generated operating cash flow of approximately $185 million," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein.  "Our Board has determined that buying back additional shares represents an attractive investment and is an appropriate means to continue building shareholder value."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Psilocybin therapy reduces depression in clinicians after pandemic frontline work